- Home
- FLGC vs NRXP Comparison
FLGC vs NRXP Comparison
Compare FLGC & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLGC
- NRXP
- Stock Information
- Founded
- FLGC 2019
- NRXP 2015
- Country
- FLGC United States
- NRXP United States
- Employees
- FLGC N/A
- NRXP N/A
- Industry
- FLGC Biotechnology: Pharmaceutical Preparations
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- FLGC Health Care
- NRXP Health Care
- Exchange
- FLGC Nasdaq
- NRXP Nasdaq
- Market Cap
- FLGC 15.5M
- NRXP 14.8M
- IPO Year
- FLGC 2021
- NRXP N/A
- Fundamental
- Price
- FLGC $1.05
- NRXP $1.50
- Analyst Decision
- FLGC Strong Buy
- NRXP Strong Buy
- Analyst Count
- FLGC 4
- NRXP 3
- Target Price
- FLGC $5.67
- NRXP $31.67
- AVG Volume (30 Days)
- FLGC 956.1K
- NRXP 317.1K
- Earning Date
- FLGC 11-13-2024
- NRXP 11-14-2024
- Dividend Yield
- FLGC N/A
- NRXP N/A
- EPS Growth
- FLGC N/A
- NRXP N/A
- EPS
- FLGC N/A
- NRXP N/A
- Revenue
- FLGC $64,154,000.00
- NRXP N/A
- Revenue This Year
- FLGC N/A
- NRXP N/A
- Revenue Next Year
- FLGC $8.94
- NRXP N/A
- P/E Ratio
- FLGC N/A
- NRXP N/A
- Revenue Growth
- FLGC N/A
- NRXP N/A
- 52 Week Low
- FLGC $0.75
- NRXP $1.10
- 52 Week High
- FLGC $2.93
- NRXP $7.33
- Technical
- Relative Strength Index (RSI)
- FLGC 36.74
- NRXP 61.95
- Support Level
- FLGC $1.60
- NRXP $1.17
- Resistance Level
- FLGC $1.22
- NRXP $1.85
- Average True Range (ATR)
- FLGC 0.20
- NRXP 0.13
- MACD
- FLGC -0.08
- NRXP 0.04
- Stochastic Oscillator
- FLGC 7.89
- NRXP 50.00
About FLGC Flora Growth Corp.
Flora Growth Corp is a multi-national cannabis company that manufactures and distributes consumer packaged goods, cultivates and distributes medicinal cannabis, and distributes pharmaceutical products. Its reportable segments are; the commercial and wholesale segment (FGH and Cosechemos subsidiaries), the house of brands segment (JustCBD, Vessel, and Kasa Wholefoods Company subsidiaries), and the pharmaceuticals segment (Grupo Farmaceutico Cronomed and Breeze Laboratory subsidiaries). Geographically, the company generates revenue from United States, Germany, and the United Kingdom. It derives a majority of its revenue from the United States.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.